Redwood Grove Capital LLC purchased a new position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 93,500 shares of the medical research company's stock, valued at approximately $18,066,000. IQVIA makes up 4.6% of Redwood Grove Capital LLC's investment portfolio, making the stock its 10th largest holding. Redwood Grove Capital LLC owned approximately 0.06% of IQVIA at the end of the most recent quarter.
A number of other institutional investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in IQVIA by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company's stock valued at $4,429,426,000 after acquiring an additional 159,899 shares during the period. BlackRock Inc. bought a new stake in shares of IQVIA in the 2nd quarter worth about $2,811,292,000. Geode Capital Management LLC grew its holdings in shares of IQVIA by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company's stock worth $982,272,000 after purchasing an additional 24,453 shares during the last quarter. Boston Partners increased its position in shares of IQVIA by 14.9% during the 4th quarter. Boston Partners now owns 4,087,380 shares of the medical research company's stock worth $923,276,000 after purchasing an additional 530,672 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in IQVIA by 16.2% during the 4th quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company's stock valued at $856,468,000 after purchasing an additional 528,753 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.
IQVIA Trading Down 0.1%
Shares of NYSE IQV opened at $259.97 on Wednesday. The company's 50 day simple moving average is $216.59 and its 200 day simple moving average is $188.02. The firm has a market capitalization of $42.79 billion, a P/E ratio of 32.25, a P/E/G ratio of 2.21 and a beta of 1.18. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $261.88. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71.
IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.03 by $0.12. The business had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The firm's revenue was up 8.7% on a year-over-year basis. During the same period last year, the company earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, analysts predict that IQVIA Holdings Inc. will post 11.57 EPS for the current year.
IQVIA announced that its Board of Directors has approved a stock buyback program on Thursday, May 7th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the medical research company to buy up to 6.8% of its shares through open market purchases. Shares buyback programs are often a sign that the company's management believes its stock is undervalued.
Wall Street Analyst Weigh In
IQV has been the topic of several research analyst reports. Wall Street Zen raised shares of IQVIA from a "hold" rating to a "buy" rating in a research note on Saturday, August 1st. Royal Bank Of Canada boosted their target price on IQVIA from $221.00 to $247.00 and gave the stock an "outperform" rating in a report on Wednesday, July 29th. JPMorgan Chase & Co. increased their price target on IQVIA from $225.00 to $285.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 29th. BMO Capital Markets increased their target price on IQVIA from $210.00 to $270.00 and gave the stock an "outperform" rating in a report on Wednesday, July 29th. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 price target on shares of IQVIA in a research report on Thursday, July 9th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, IQVIA has a consensus rating of "Moderate Buy" and an average price target of $241.88.
Check Out Our Latest Analysis on IQVIA
Insider Buying and Selling
In other news, insider Bhavik Patel sold 1,855 shares of the company's stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $235.27, for a total value of $436,425.85. Following the completion of the sale, the insider directly owned 1,348 shares of the company's stock, valued at $317,143.96. This represents a 57.91% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Eric Sherbet sold 5,000 shares of the stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the completion of the sale, the insider owned 20,999 shares in the company, valued at $5,232,110.84. This represents a 19.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 12,913 shares of company stock valued at $3,098,793. Insiders own 1.70% of the company's stock.
IQVIA Profile
(
Free Report)
IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.
IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
